Bryan Lawlis is listed as a director on 3 SEC Form D filings by 2 issuers between Apr 2016 and Dec 2019: AbSci Corp (Vancouver, WA — biotechnology — 2016–2019; $125M reported sold to 31 investors) and SUTRO BIOPHARMA INC (South San Francisco, CA — biotechnology — 2018; $85.4M reported sold to 15 investors).
What this means 2 separate companies raised money with this person listed as director, over about 3 years. Across those companies the filings report $210.4M sold in total.
Listed alongside Daniel Gold (2 shared filings), Sean McClain (2 shared filings), Zach Jonasson (2 shared filings), Armen Shanafelt (1 shared filing), Daniel Janney (1 shared filing) and 7 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Bryan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 2 court cases matching the name listed in Key records below.
What this means 2 records came back, including 2 court cases still open — open cases can take years and cost money. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Bryan Lawlis and found 8 differences, 1 worth asking the sponsor about: Bryan Lawlis is no longer listed on the Aug 8, 2018 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.